氯喹、羟氯喹和奎宁中毒的体外治疗:EXTRIP工作组的系统评价与推荐
EXTRIP工作组系统检索并分析了44项研究(3项体外、2项动物、28项病例报告或病例系列、11项药代动力学研究),其中61例有毒性/药代动力学数据(氯喹13例、羟氯喹3例、奎宁45例),38例有临床数据(氯喹12例、羟氯喹1例、奎宁25例)。三种药物均被归类为不可透析(体外治疗不能实现临床显著清除)。数据不支持对严重氯喹或奎宁中毒患者在标准治疗外加用体外治疗(强推荐,证据质量极低);羟氯喹虽评为不可透析,但临床证据不足以形成正式推荐。
要点
- 三种药物(氯喹、羟氯喹、奎宁)均被EXTRIP归类为不可透析,体外治疗不能实现临床显著清除。
- 严重氯喹或奎宁中毒:EXTRIP强烈推荐不应在标准治疗外加用体外治疗清除药物(证据质量极低)。
- 羟氯喹中毒:评为不可透析,但临床证据不足以形成关于体外治疗的正式推荐。
- 证据基础薄弱:共44项研究,仅38例临床数据(氯喹12例、羟氯喹1例、奎宁25例)。
适用人群与场景
- 氯喹、羟氯喹或奎宁中毒的患者(研究纳入病例报告、病例系列及药代动力学研究中的中毒病例)。
处置流程与药物剂量
- 对严重氯喹或奎宁中毒患者,EXTRIP强烈推荐不应在标准治疗外加用体外治疗以增强药物清除(强推荐,证据质量极低)。
- 对羟氯喹中毒,因临床证据不足,未形成关于体外治疗的正式推荐。
研究设计与关键结果
- 系统评价共纳入44项研究:3项体外研究、2项动物研究、28项病例报告或病例系列、11项药代动力学研究。
- 61例患者有毒性/药代动力学分析数据:氯喹13例、羟氯喹3例、奎宁45例。
- 38例患者有临床数据可供分析:氯喹中毒12例、羟氯喹中毒1例、奎宁中毒25例。
- 三种药物均被归类为不可透析(体外治疗不能实现临床显著清除)。
- 数据不支持对严重氯喹或奎宁中毒患者在标准治疗外加用体外治疗(强推荐,证据质量极低)。
- 羟氯喹评为不可透析,但临床证据不足以形成正式推荐。
证据类型、等级与局限
- 证据类型:EXTRIP工作组系统评价(纳入体外研究、动物研究、病例报告/系列及药代动力学研究)。
- 推荐强度:对氯喹和奎宁为强推荐,证据质量极低。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对严重氯喹或奎宁中毒,不应在标准治疗外加用体外治疗来增强药物清除(EXTRIP强推荐,证据质量极低)。
- 对羟氯喹中毒,体外治疗的使用尚无正式推荐,临床决策需个体化。
指南或共识出处
- EXTRIP工作组系统评价与推荐(J Am Soc Nephrol)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.
METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.
RESULTS: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.
CONCLUSIONS: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.
参考来源
- Berling I, King JD, Shepherd G, et al. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. J Am Soc Nephrol. 2020. PMID: 32963091. doi:10.1681/ASN.2020050564
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。